医药生物行业资金流出榜 （原标题：14.41亿元主力资金今日抢筹医药生物板块） 沪指6月23日上涨0.65%，申万所属行业中，今日上涨的有28个，涨幅居前的行业为计算机、国防军工，涨幅分别为2.25%、1.97%。医药生物行业 今日上涨0.89%。跌幅居前的行业为食品饮料、家用电器、钢铁，跌幅分别为0.80%、0.43%、0.11%。 医药生物行业今日上涨0.89%，全天主力资金净流入14.41亿元，该行业所属的个股共475只，今日上涨的有400只，涨停的有6只；下跌的有65只， 跌停的有1只。以资金流向数据进行统计，该行业资金净流入的个股有247只，其中，净流入资金超亿元的有5只，净流入资金居首的是永安药业， 今日净流入资金2.35亿元，紧随其后的是塞力医疗、华海药业，净流入资金分别为1.65亿元、1.25亿元。医药生物行业资金净流出个股中，资金净 流出超3000万元的有9只，净流出资金居前的有众生药业、创新医疗、新诺威，净流出资金分别为1.42亿元、6423.29万元、5901.06万元。（数据 宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, enhancing its product line in the treatment of mental disorders and increasing market competitiveness [2] Group 1: Product Approvals and Market Potential - The Fumaric Acid Quetiapine Sustained-Release Tablets are developed by AstraZeneca and are primarily used for treating schizophrenia and depressive episodes in bipolar disorder, with a projected domestic market sales of approximately 451 million yuan in 2024 [2] - Huahai Pharmaceutical has recently received multiple drug approvals, indicating strong R&D capabilities and pipeline efficiency, including Dagagliflozin Metformin Sustained-Release Tablets and Tolvaptan Tablets, with projected sales of approximately 195 million yuan and 497 million yuan respectively in 2024 [2] Group 2: Business Growth and Revenue - The formulation business is becoming a growth engine for Huahai Pharmaceutical, with revenue expected to increase from 4.721 billion yuan in 2022 to 5.759 billion yuan in 2024, raising its revenue share from 57.11% to 60.32% [3] - The company has 105 formulation products approved by the US ANDA and 79 products approved by the National Medical Products Administration, covering various therapeutic areas including cardiovascular, mental disorders, and infections [3] Group 3: Strategic Initiatives and Innovations - Huahai Pharmaceutical is committed to advancing its biological innovation drug strategy, with significant investments in R&D for innovative drugs, particularly in oncology and autoimmune diseases [4] - The company’s subsidiary, Shanghai Huatai Biological Pharmaceutical Co., Ltd., is preparing to submit an ANDA for its HB0034 project, aimed at treating generalized pustular psoriasis, with expected approval next year [4]

股票简称：华海药业 股票代码：600521 公告编号：临 2025-072 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于部分回购股份注销实施暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 5 月 23 日分别召开第八届董事会第三次会议和 2024 年年度股东大会，会议审议 通过了《关于注销部分回购股份并减少注册资本的议案》，同意公司对回购专用证券 账户中的 10,656,753 股股份予以注销，并相应减少公司注册资本。本次注销完成后， 公 司 总 股 本 将 由 1,507,907,834 股 变 更 为 1,497,251,081 股 ， 公 司 注 册 资 本 将 由 ? 股份注销日：2025 年 6 月 16 日。 一、回购股份情况概述 公司分别于 2021 年 4 月 23 日、2021 年 5 月 18 日召开第七届董事会第二次会 议、2020 年 ...

Core Viewpoint - The report discusses the adjustment of the conversion price for Zhejiang Huahai Pharmaceutical Co., Ltd.'s convertible bonds, following the company's decision to cancel part of its repurchased shares, which will affect the bondholders' rights and the bond's conversion terms [1][16]. Group 1: Bond Issuance Details - The total amount of the convertible bonds issued by the company is RMB 1,842.60 million, with a face value of RMB 100 per bond [3]. - The bonds were issued on November 2, 2020, and have a maturity period of six years, expiring on November 1, 2026 [3][4]. - The coupon rates for the bonds are set at 0.30% for the first year and 0.50% for the second year, with subsequent rates to be determined [4]. Group 2: Conversion Price Adjustment - The initial conversion price for the bonds was set at RMB 34.66 per share, which is subject to adjustments based on various corporate actions such as stock dividends and capital increases [5][16]. - Following the cancellation of 10,656,753 shares, the conversion price will be adjusted from RMB 33.21 to RMB 33.31 per share, effective from June 17, 2025 [16]. - The adjustment formula considers factors such as stock dividends, new share issuance, and cash dividends, ensuring that bondholders' rights are protected [14][15]. Group 3: Impact on the Company - The adjustment of the conversion price is in compliance with the terms outlined in the bond issuance prospectus and does not adversely affect the company's operational or debt repayment capabilities [16]. - The company will continue to monitor the repayment of the convertible bonds and any significant impacts on bondholders' rights [16].

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-072 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 5 月 23 日分别召开第八届董事会第三次会议和 2024 年年度股东大会，会议审议 通过了《关于注销部分回购股份并减少注册资本的议案》，同意公司对回购专用证券 账户中的 10,656,753 股股份予以注销，并相应减少公司注册资本。本次注销完成后， 公司总股本将由 1,507,907,834 股变更为 1,497,251,081 股，公司注册资本将由 1,507,907,834 元变更为 1,497,251,081 元。 股份注销日：2025 年 6 月 16 日。 一、回购股份情况概述 公司分别于 2021 年 4 月 23 日、2021 年 5 月 18 日召开第七届董事会第二次会 议、2020 年年度股东大会，审议通过《关于以集中竞价交易方式回购公司股份方案 的议案》；2 ...

证券代码：600521 证券简称：华海药业 债券代码：110076 债券简称：华海转债 浙商证券股份有限公司 关于 浙江华海药业股份有限公司 可转换公司债券转股价格调整的 临时受托管理事务报告 债券受托管理人： （浙江省杭州市五星路 201 号） 二〇二五年六月 1 重要声明 浙商证券股份有限公司（以下简称"浙商证券"）编制本报告的内容及信息 来源于浙江华海药业股份有限公司（以下简称"华海药业"、"公司"或"发行人"） 对外公布的公开信息披露文件及发行人向浙商证券提供的资料。 浙商证券按照《公司债券发行与交易管理办法》《公司债券受托管理人执业 行为准则》等相关规定及与华海药业签订的《浙江华海药业股份有限公司公开发 行可转换公司债券之受托管理协议》（以下简称"《受托管理协议》"）的约定编制 本报告。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为浙商证券所作的承诺 或声明。请投资者独立征询专业机构意见，在任何情况下，投资者不能将本报告 作为投资行为依据。 浙商证券提请投资者及时关注发行人的信息披露文件，并已督促发行人及时 履行信息披露义务 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2025-074 号 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 富马酸喹硫平缓释片用于治疗精神分裂症和双相情感障碍的抑郁发作。富马酸 喹硫平缓释片最早由阿斯利康（AstraZeneca）公司研发，于 2007 年 5 月在美国上 市，国内于 2013 年 10 月批准上市。目前国内获得该药品注册证书的主要有吉林天 衡药业有限公司、丽珠集团丽珠制药厂等。根据米内网数据预测，富马酸喹硫平缓 释片 2024 年国内市场销售金额约人民币 4.51 亿元。 截止目前，公司在富马酸喹硫平缓释片研发项目上已投入研发费用约人民币 1,693 万元。 三、对公司的影响 1 本次富马酸喹硫平缓释片获得国家药监局的《药品注册证书》，进一步丰富了 公司的产品线，有助于提升公司产品的市场竞争力，对公司的经营发展具有一定积 极的作用。 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2025-073 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于因回购股份注销调整"华海转债"转股价格 因授予限制性股票增发股份，华海转债的转股价格由 34.46 元/股调整为 33.85 元/股，具体内容详见公司于 2021 年 7 月 10 日刊登在中国证券报、上海证券报、 证券时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的《浙江华海药 业股份有限公司关于授予限制性股票增发股份调整可转债转股价格的公告》（公告 编号：临 2021-065 号）。 因向激励对象授予预留部分限制性股票，华海转债的转股价格由 33.85 元/股 调整至 33.79 元/股，具体内容详见公司于 2022 年 5 月 27 日刊登在中国证券报、 上海证券报、证券时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的 《浙江华海药业股份有限公司关于授予限制性股票增发股份调整可转债转股价格 的公告》（公告编号：临 2022-064 号）。 暨转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Extended-Release Tablets, which are used to treat schizophrenia and depressive episodes of bipolar disorder [1] Summary by Relevant Categories Product Approval - The approved drug was originally developed by AstraZeneca and was launched in the United States in 2007 [1] - The approval of this drug enhances the company's product line and improves its market competitiveness [1] Market Potential - According to data from Minet, the projected domestic market sales for this drug are approximately 451 million yuan in 2024 [1] R&D Investment - The company has invested approximately 16.93 million yuan in the research and development of this project [1]

Policy Developments - The Central Committee and State Council issued an opinion to improve the adjustment mechanism for the basic medical insurance drug catalog and to establish an innovative drug catalog for commercial health insurance [2] - The opinion aims to promote the sharing of high-quality medical resources and enhance the capacity of grassroots medical institutions [2] - The commercial health insurance sector is becoming a crucial lever for the high-quality development of commercial health insurance, helping to address the payment challenges for innovative drugs [3] Medical Device Approvals - DaAn Gene obtained a medical device registration certificate for six nucleic acid test kits for respiratory pathogens, expanding its product portfolio [5] - BGI Innovation received a medical device registration certificate for a human papillomavirus genotyping test kit, classified as Class III [6] - Shanghai Pharmaceuticals received approval for the production of Formoterol Fumarate inhalation solution, which is used for the maintenance treatment of chronic obstructive pulmonary disease [7] Corporate Transactions - Pilin Bio announced the resumption of trading after China National Pharmaceutical Group acquired 21.03% of its shares, changing the controlling shareholder [8] - China General Nuclear Power Corporation plans to inject 500 million yuan into its subsidiary for proton medical research and development [9] - Zhonghui Pharmaceutical completed two rounds of financing totaling nearly 50 million yuan, which will be used for the construction of a hollow microneedle medical device production base [10] Industry Developments - Dongxing Medical's subsidiary signed two contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan [11] Regulatory Alerts - Huahai Pharmaceutical received a warning letter from the FDA regarding its production facility, which may affect future ANDA applications but will not significantly impact current performance [12]